Devang Sharma, MD
Urology · Bethesda, MDNPI 1114346004
Payments from drug & device makers
Across 262 payments — averaging $44.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teleflex LLC$2K
- Boston Scientific$2K
- Coloplast$2K
- Dornier Medtech America, Inc$503
- Endo Pharmaceuticals Inc.$485
- Urogen Pharma, Inc.$458
- plus $4K from 30 others
What the payments were for
- Speaking & faculty fees$1121%
- Travel & lodging$2,11718%
- Food & beverage$9,35480%
- Education$901%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teleflex LLC | 28 | $2,466 |
| Boston Scientific | 42 | $2,143 |
| Coloplast | 15 | $1,637 |
| Dornier Medtech America, Inc | 1 | $503 |
| Endo Pharmaceuticals Inc. | 16 | $485 |
| Urogen Pharma, Inc. | 17 | $458 |
| Antares Pharma, Inc. | 18 | $394 |
| AbbVie(2 entities) | 16 | $380 |
| Astellas Pharma US Inc | 16 | $364 |
| Bayer | 14 | $340 |
| Endo USA, Inc. | 12 | $313 |
| Sumitomo Pharma America, Inc. | 10 | $293 |
| Johnson & Johnson(2 entities) | 10 | $261 |
| Axonics, Inc. | 3 | $218 |
| Olympus America Inc. | 4 | $201 |
| Tolmar, Inc. | 5 | $194 |
| Immunitybio, Inc. | 2 | $159 |
| Progenics Pharmaceuticals, Inc. | 2 | $133 |
| Novartis | 3 | $72 |
| Halozyme Inc | 3 | $68 |
| Accord Healthcare, Inc. | 3 | $64 |
| Laborie Medical Technologies Corp. | 1 | $63 |
| 180 Medical, Inc. | 2 | $56 |
| Lantheus Medical Imaging, Inc. | 2 | $54 |
| Telix Pharmaceuticals | 2 | $52 |
| Azurity Pharmaceuticals, Inc. | 2 | $42 |
| Medtronic | 1 | $41 |
| Acerus Pharmaceuticals Corporation | 2 | $33 |
| Myriad Genetic Laboratories, Inc. | 2 | $31 |
| Pfizer | 1 | $26 |
| Clarus Therapeutics Inc. | 2 | $26 |
| ABC Home Medical Supply, Inc. | 1 | $25 |
| Photocure Inc | 1 | $23 |
| Merck | 1 | $20 |
| Blue Earth Diagnostics | 1 | $17 |
| Verity Pharmaceuticals Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UroLift$1,596
- TITAN$1,511
- AMS 700 CXR RTE KIT$623
- Dornier MedTech$503
- GENERAL ERECTILE DYSFUNCTION$354
- AMS 700$236
- Axonics$160
- Barrigel$147
- ANKTIVA$135
- iTIND System$135
- SpaceOAR VUE System - 10mL$125
- XIAFLEX$123
- PYLARIFY$114
- ORGOVYX$112
- AMS 800 Artificial Urinary Sphincter$108
How this compares
$11,673 in reported general payments places this provider in the 70th percentile of 274 urology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 63 | $62,750 |
| XyostedTestosterone Enanthate | 34 | $32,618 |
| Finasteride | 202 | $2,995 |
| Tamsulosin Hcl | 174 | $2,568 |
| Testosterone Cypionate | 46 | $2,283 |
| Dutasteride | 30 | $1,773 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 69 | $1,428 |
| Oxybutynin Chloride ErOxybutynin Chloride | 13 | $318 |
| Doxycycline Monohydrate | 22 | $233 |
| Cephalexin | 15 | $60 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 16 | $33 |
| Oxycodone Hcl | 12 | $12 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $364 | $62,75063 claims |
| Antares Pharma, Inc.Xyosted | $394 | $32,61834 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 274 urology providers in Maryland.
Other urology in Bethesda
- Rachel RubinBethesda$91K
- Bartholomew RadolinskiBethesda$90K
- Gregory ChesnutBethesda$25K
- Matthew AllawayCumberland$20.6M
- Ronald TutroneBaltimore$18.1M
- Mohamad AllafBaltimore$7.1M
- Max KatesBaltimore$1000K
- Benjamin LowentrittBaltimore$994K
- Rian DicksteinHanover$750K
- Laura GiustoOwings Mills$628K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.